Trial · NCT02206763
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT02206763, Phase 1, Terminated, Sierra Oncology LLC - a GSK company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC). Trials, record NCT02206763. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02206763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
- NCT number
- NCT02206763
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 11 participants, actual
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Conditions
- EGFR Mutated EGFR TKI Naive Metastatic NSCLC
- Interventions
- Momelotinib (MMB), Erlotinib
- First posted
- 2014-08-01
- Last updated
- 2019-02-01
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dose Limiting Toxicities (DLTs) | Up to 28 days | Dose limiting toxicities refer to toxicities experienced during the first 28 days of combined erlotinib and momelotinib (MMB) treatment that have been judged to be clinically significant and related to study treatment. |
| Primary | Safety as Assessed by the Incidence of Adverse Events (AEs) | Up to 2 years plus 30 days | |
| Primary | Safety as Assessed by the Percentage of Participants Experiencing Treatment-Emergent Graded Lab Abnormalities (including Chemistry, Coagulation, Hematology, and Urinalysis) | Up to 2 years plus 30 days | |
| Primary | Change from Baseline in Vital Signs | Up to 2 years | |
| Secondary | Progression-Free Survival | Until disease progression (up to 2 years) | Progression-free survival is defined as the interval from first dose date of study drug (MMB/erlotinib) to the earlier of the first documentation of definitive disease progression or death from any cause; definitive disease progression is progression based on RECIST criteria v1.1. |
| Secondary | Overall Survival | Until disease progression (up to 2 years) | Overall survival is defined as the interval from first dose date of study drug (MMB/erlotinib) to death from any cause. |
| Secondary | Overall Response Rate | Until disease progression (up to 2 years) | Overall response rate is defined as the proportion of participants who achieve a complete response or partial response. |
| Secondary | Pharmacokinetic (PK) Parameter: Cmax of momelotinib (MMB) | Predose and up to 24 hours postdose | Cmax is defined as the maximum observed concentration of drug. |
| Secondary | PK Parameter: AUCtau of momelotinib (MMB) | Predose and up to 24 hours postdose | AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). |
| Secondary | PK Parameter: Cmax of Erlotinib | Predose and up to 24 hours postdose | Cmax is defined as the maximum observed concentration of drug. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34773474 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02206763
GET https://conductscience.org/api/trials/v1/NCT02206763/registered